LYVDELZI 10 mg HARD CAPSULES
How to use LYVDELZI 10 mg HARD CAPSULES
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the Patient
Lyvdelzi 10 mg Hard Capsules
seladelpar
This medicine is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may experience. The last section of section 4 will tell you how to report side effects.
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor, pharmacist, or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the Package Leaflet
- What is Lyvdelzi and what is it used for
- What you need to know before you take Lyvdelzi
- How to take Lyvdelzi
- Possible side effects
- Storage of Lyvdelzi
- Contents of the pack and further information
1. What is Lyvdelzi and what is it used for
What is Lyvdelzi
Lyvdelzi contains the active substance seladelpar. It belongs to a group of medicines called peroxisome proliferator-activated receptor delta (PPARδ) agonists.
This medicine is used in adults to treat primary biliary cholangitis (PBC), a liver disease in which the bile ducts are slowly destroyed, making it difficult for bile to pass through. Bile is a liquid that helps digest food, especially fats. When bile cannot pass through the digestive tract, it builds up in the liver (this is called cholestasis) and damages liver tissue. This can reduce liver function and cause inflammation. Lyvdelzi can be used alone or with another medicine called ursodeoxycholic acid (UDCA) in patients who cannot tolerate UDCA.
The active substance in Lyvdelzi, seladelpar, works by activating the PPAR delta receptor. This protein regulates bile acid levels, inflammation, and fibrosis (scar tissue formation). This reduces bile production and accumulation in the liver and also reduces liver inflammation.
2. What you need to know before you take Lyvdelzi
Do not take Lyvdelzi:
- if you are allergic to seladelpar or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Your doctor may perform blood tests before you start treatment with Lyvdelzi and during treatment to check if your liver is working properly (liver function). If the tests show that your liver function has worsened, your doctor may need to stop treatment. If your liver recovers, you may be able to start treatment again. If your liver function worsens again after restarting treatment, your doctor may permanently stop treatment with Lyvdelzi. Contact your doctor immediately if you develop symptoms of liver dysfunction (liver inflammation) or complete biliary obstruction (blocked bile ducts) during treatment, including:
- abdominal pain
- jaundice (yellowing of the skin and whites of the eyes)
- dark urine
- light-colored stools
Children and adolescents
Lyvdelzi should not be given to children and adolescents under 18 years of age.
Other medicines and Lyvdelzi
Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines or herbal remedies.
In particular, tell your doctor, pharmacist, or nurse if you are taking a medicine called:
- probenecid, used to treat gout
- cyclosporin, used to prevent the body from rejecting a transplanted organ
- bile acid sequestrants (such as cholestyramine, colestipol, or colesevelam), used to lower cholesterol levels in the blood. These may reduce the effectiveness of Lyvdelzi if taken too close to Lyvdelzi.
- If you take a bile acid sequestrant, take Lyvdelzi at least 4 hours before or at least 4 hours after taking the bile acid sequestrant. See section 3 for more information.
The following medicines may increase the risk of side effects with Lyvdelzi, as they increase the amount of Lyvdelzi in the blood:
- fluconazole, used to treat fungal infections
- mifepristone, used for medical termination of pregnancy
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
This medicine is unlikely to affect your ability to drive or use tools or machines.
Lyvdelzi contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per hard capsule; this is essentially "sodium-free".
3. How to take Lyvdelzi
Always take this medicine exactly as your doctor, pharmacist, or nurse has told you. If you are not sure, check with your doctor, pharmacist, or nurse.
How much to take
The recommended dose is one 10 mg capsule once a day.
How to take
- Swallow the capsule whole with water
- You can take this medicine with or without food
- Lyvdelzi is taken with another medicine called ursodeoxycholic acid (UDCA) or alone, if you cannot take UDCA
If you are already taking a bile acid sequestrant:
- Take Lyvdelzi at least 4 hours before or at least 4 hours after taking the bile acid sequestrant
- If you are unsure, ask your doctor, pharmacist, or nurse
If you take more Lyvdelzi than you should
If you take more Lyvdelzi than you should, contact your doctor, pharmacist, or nurse immediately.
Symptoms of overdose include dark urine or muscle pain.
If you forget to take Lyvdelzi
If you forget to take Lyvdelzi, skip the missed dose and take the next dose when it is due.
Do not take a double dose to make up for a forgotten dose.
If you stop taking Lyvdelzi
Do not stop taking this medicine without talking to your doctor, pharmacist, or nurse.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Side effects
Tell your doctor, pharmacist, or nurse if you notice any of the following side effects.
Very common:may affect more than 1 in 10 people
- abdominal pain
Common:may affect up to 1 in 10 people
- headache
- nausea
- abdominal distension (swelling of the abdomen)
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Lyvdelzi
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after "EXP". The expiry date refers to the last day of the month shown.
Do not store this medicine at a temperature above 30°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
6. Contents of the pack and further information
Composition of Lyvdelzi
- The active substance is seladelpar.
- Each hard capsule of Lyvdelzi contains 10 mg of seladelpar.
- The other ingredients are:
- capsule content: microcrystalline cellulose, mannitol, sodium croscarmellose, butylhydroxytoluene, magnesium stearate, colloidal silicon dioxide
- capsule shell: gelatin, titanium dioxide, iron oxide black (E172), iron oxide red (E172), iron oxide yellow (E172), indigo carmine (E132)
- black ink used to print "10" on the body of the capsule: shellac (E904), propylene glycol (E1520), potassium hydroxide (E525), iron oxide black (E172)
- white ink used to print "CBAY" on the capsule cap: shellac (E904), propylene glycol (E1520), sodium hydroxide (E524), povidone (E1201), titanium dioxide
Do not take Lyvdelzi if you are allergic to any of the ingredients, listed in section 2.
Appearance and packaging of the product
This medicine is a hard capsule with a dark blue opaque cap and a light gray opaque body, with "CBAY" printed in white ink on the cap and "10" printed in black ink on the body. The capsules are packaged in a child-resistant closure bottle. Each bottle contains 30 capsules.
Marketing authorisation holder
Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Ireland
Manufacturer
Gilead Sciences Ireland UC
IDA Business and Technology Park
Carrigtohill
Co. Cork
Ireland
You can request more information about this medicine from the local representative of the marketing authorisation holder:
Belgium/België/Belgien Gilead Sciences Belgium SRL-BV Tel: + 32 (0) 24 01 35 50 | Lithuania Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
| Luxembourg/Luxemburg Gilead Sciences Belgium SRL-BV Tel: + 32 (0) 24 01 35 50 |
Czech Republic Gilead Sciences s.r.o. Tel: + 420 910 871 986 | Hungary Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Denmark Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 | Malta Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Germany Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0 | Netherlands Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 98 |
Estonia Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | Norway Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Greece Gilead Sciences Ελλάς Μ.ΕΠΕ. Tel: + 30 210 8930 100 | Austria Gilead Sciences GesmbH Tel: + 43 1 260 830 |
Spain Gilead Sciences, S.L. Tel: + 34 91 378 98 30 | Poland Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 |
France Gilead Sciences Tel: + 33 (0) 1 46 09 41 00 | Portugal Gilead Sciences, Lda. Tel: + 351 21 7928790 |
Croatia Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | Romania Gilead Sciences (GSR) S.R.L. Tel: + 40 31 631 18 00 |
Ireland Gilead Sciences Ireland UC Tel: + 353 (0) 214 825 999 | Slovenia Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Iceland Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 | Slovakia Gilead Sciences Slovakia s.r.o. Tel: + 421 232 121 210 |
Italy Gilead Sciences S.r.l. Tel: + 39 02 439201 | Finland Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Cyprus Gilead Sciences Ελλάς Μ.ΕΠΕ. Tel: + 30 210 8930 100 | Sweden Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Latvia Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Date of last revision of this leaflet:
This medicine has been authorised with a "conditional approval". This type of approval means that more information on this medicine is expected.
The European Medicines Agency will review new information on this medicine at least once a year and this leaflet will be updated as necessary.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website https://www.ema.europa.eu.
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to LYVDELZI 10 mg HARD CAPSULESDosage form: CAPSULE, 1200 µgActive substance: odevixibatManufacturer: Ipsen PharmaPrescription requiredDosage form: CAPSULE, 200 µgActive substance: odevixibatManufacturer: Ipsen PharmaPrescription requiredDosage form: CAPSULE, 200 - REVIEW µgActive substance: odevixibatManufacturer: Ipsen PharmaPrescription required
Online doctors for LYVDELZI 10 mg HARD CAPSULES
Discuss questions about LYVDELZI 10 mg HARD CAPSULES, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions
